Tanomastat

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameTanomastat
Drug Alias Name坦诺司他TanomastatumBAY-12-9566
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMatrix metalloproteinase 9 inhibitorsMatrix metalloproteinase 3 inhibitorsMatrix metalloproteinase-2 inhibitors
TargetsMatrix metalloproteinase 9Matrix metalloproteinase 3Matrix metalloproteinase-2
Therapy Area/IndicationsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBayer AG
Active IndicationsN/A
Inactive IndicationsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungOvarian Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG